富白细胞和血小板纤维蛋白在颅脑手术中的应用:一项前瞻性、平行组、单盲随机对照非劣效性试验的研究方案
该试验为单盲、前瞻性随机对照干预试验,旨在证明自体富白细胞和血小板纤维蛋白(L-PRF)用于硬脑膜闭合时不劣于市售纤维蛋白密封剂。纳入硬脑膜被有意切开的幕上及幕下颅脑手术患者,按1:1随机分组,主要终点为术后12周内脑脊液漏。
要点
- L-PRF与市售纤维蛋白密封剂在硬脑膜闭合中比较,主要终点为术后12周内脑脊液漏。
- 试验为单盲、前瞻性、平行组、随机对照非劣效性设计,患者按1:1随机分组。
- 次要终点包括出血或伤口感染等并发症,并进行成本效果分析。
核心结论
- 该试验将评估L-PRF与市售纤维蛋白密封剂相比在硬脑膜闭合中的安全性和有效性。
研究设计与样本
- 单盲、前瞻性随机对照干预试验,采用平行组设计,旨在证明L-PRF相对于市售纤维蛋白密封剂的非劣效性。
- 纳入接受幕上及幕下颅脑神经外科手术且硬脑膜被有意切开的患者。
- 患者按1:1比例随机分配至L-PRF组或市售纤维蛋白密封剂组。
主要发现
- 主要终点为术后12周内脑脊液漏。
- 次要终点为出血或伤口感染等并发症。
- 同时进行成本效果分析。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: CSF leakage is a major complication after cranial surgery, thus, adequate dural closure must be performed. Commercially available fibrin sealants are currently considered the gold standard for dural closure, but problems have been reported regarding safety, efficacy, and costs. This trial aims to investigate autologous leukocyte- and platelet-rich fibrin (L-PRF) as an alternative to commercially available fibrin sealants. METHODS/DESIGN: This single-blinded, prospective randomized controlled interventional trial aims to demonstrate the non-inferiority of L-PRF compared to commercially available fibrin sealants for dural closure. This trial will include patients undergoing cranial neurosurgery (supratentorial and infratentorial) with intentional opening of the dura. Patients are randomized in a 1:1 fashion comparing L-PRF to commercially available fibrin sealants. The primary endpoint is postoperative CSF leakage within 12 weeks after surgery. Secondary endpoints are complications such as bleeding or wound infections. Additionally, a cost-effectiveness analysis is performed. DISCUSSION: With this trial, we will evaluate the safety and efficiency of L-PRF compared to commercially available fibrin sealants. TRIAL REGISTRATION: ClinicalTrials.gov NCT03812120. Registered on 22 January 2019.
引用
- Coucke B, Van Hoylandt A, van Loon J, et al. Leukocyte- and platelet-rich fibrin in cranial surgery: study protocol for a prospective, parallel-group, single-blinded randomized controlled non-inferiority trial {1}. Trials. 2023. PMID: 36959672. doi:10.1186/s13063-023-07252-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。